A
Alcista
Alcista · 25%SBFM
$1.99
Precio del escenario
$2.705
-0.083 (-3.05%)Al cierre
Loading chart…
- Máximo
- 2.850
- Apertura
- 2.730
- Precio medio ponderado por volumen
- 2.74
- Volumen
- 36.20K
- Capitalización
- 8.33M
- Mínimo
- 2.680
- Importe
- 99.37K
- EV/EBITDA, TTM
- 1.46
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Análisis de IA of Sunshine Biopharma Inc (SBFM)
VenderSunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.
Métricas de valoración
El PER previsto actual de Sunshine Biopharma Inc (SBFM) es 0.00, frente a su media de 5 años de -1.93.
Escenarios de precio de Alphio AI para SBFM
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SBFM en cartera
Cronología de eventos
Noticias
5.009-24NASDAQ.COMSunshine Biopharma Launches Generic Ondansetron in Canada
5.009-24NASDAQ.COMSunshine Biopharma Launches Generic Ondansetron in Canada
2.008-26NewsfiltermRNA Cancer Vaccines Show Promising Market Potential and Growth
2.006-02NASDAQ.COMBiotech Stocks Show Strong Pre-Market Moves
8.506-02NASDAQ.COMSunshine Biopharma Shares Surge 66% After Reverse Split and Drug Approval
Preguntas frecuentes sobre SBFM, respondidas por Alphio AI
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.